A reclassification petition is a formal submission asking FDA to change the regulatory classification of a generic type of device. Section 513(e) of the FD&C Act authorizes FDA-initiated reclassification; Section 513(f)(3) authorizes manufacturer-initiated petitions. Petitions must include valid scientific evidence showing that the device type warrants a different classification, typically that risks can be adequately controlled by general or special controls (down-classification from III to II) or that existing controls are insufficient (up-classification).

Why it matters

Reclassification is uncommon but strategically powerful. Down-classifying a Class III device type to Class II eliminates the PMA burden for the entire device class, affecting every competitor. FDA periodically reclassifies device types based on accumulated post-market evidence (e.g., reclassification of certain external defibrillators, some surgical staplers). Manufacturer-initiated petitions typically come from industry consortia rather than individual companies because the benefits accrue to all competitors.

Common pitfalls

•Treating a reclassification petition as a substitute for a 510(k) or De Novo, petitions reclassify the entire generic type, not individual products.
•Underestimating the evidence bar, FDA requires comprehensive scientific evidence about the device type's risk profile across the market.
•Ignoring the public comment and Federal Register process, reclassifications go through formal rulemaking.

Sources

Reclassification of Medical Devices Guidance · FDA
21 CFR Part 860 Subpart C · eCFR
IMDRF Documents · IMDRF

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.